📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Alector

1.1 - Company Overview

Alector Logo

Alector

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of neuroimmunology- and human genetics-informed antibody therapeutics for neurodegenerative diseases, with a pipeline including AL001 (targets progranulin for frontotemporal dementia with granulin mutation, Phase 3), AL002 (targets TREM2 to enhance microglia for Alzheimer's, Phase 2b), AL101 (increases progranulin for Alzheimer's/Parkinson's, Phase 2), and preclinical ABC candidates ADP027-ABC (GPNMB) and ADP050-ABC (GCase).

Products and services

  • AL002: A neuroimmunology-driven therapeutic candidate targeting TREM2 to enhance microglia activity for Alzheimer's disease, currently in Phase 2b clinical trials
  • AL001: An antibody-based therapeutic candidate targeting progranulin for the treatment of frontotemporal dementia with granulin mutation, currently in Phase 3 clinical trials
  • AL101: A human genetics-guided therapeutic candidate designed to increase progranulin levels for treating neurodegenerative diseases like Alzheimer's and Parkinson's, currently in Phase 2 clinical trials

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Alector

Canbex Therapeutics Logo

Canbex Therapeutics

HQ: United Kingdom Website
  • Description: Provider of treatments for spasticity in multiple sclerosis (MS) and other disorders, targeting the debilitating symptom of involuntary spasms and stiffness of limbs and torso, with a lead programme focused on improving the lives of people with this serious and incurable disorder.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Canbex Therapeutics company profile →
AZ Therapies Logo

AZ Therapies

HQ: United States Website
  • Description: Provider of clinical-stage biotech R&D aimed at breakthrough treatments for neuroinflammation-related diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full AZ Therapies company profile →
Grin Therapeutics Logo

Grin Therapeutics

HQ: United States Website
  • Description: Provider of targeted therapies for rare, severe neurodevelopmental disorders.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Grin Therapeutics company profile →
Impulse Monitoring Logo

Impulse Monitoring

HQ: United States Website
  • Description: Provider of intraoperative neurophysiologic monitoring solutions to hospitals and other healthcare facilities, offering insight into the nervous system during spinal, nerve, and brain-related surgeries. Solutions include IONM delivering real-time data and alerts to help reduce surgical risk, plus EEG, ECoG, EMG, and SSEP for diagnosis and intraoperative monitoring.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Impulse Monitoring company profile →
Arkis Biosciences Logo

Arkis Biosciences

HQ: United States Website
  • Description: Provider of advanced implantable technology, including catheters and minimally invasive neurosurgical instrumentation. Develops, markets, and sells proprietary catheters incorporating Endexo, intended to reduce catheter-related complications, and instrumentation designed to be less invasive across a variety of neurosurgical procedures.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Arkis Biosciences company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Alector

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Alector

2.2 - Growth funds investing in similar companies to Alector

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Alector

4.2 - Public trading comparable groups for Alector

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Alector

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Alector

What does Alector do?

Alector is a provider of neuroimmunology- and human genetics-informed antibody therapeutics for neurodegenerative diseases, with a pipeline including AL001 (targets progranulin for frontotemporal dementia with granulin mutation, Phase 3), AL002 (targets TREM2 to enhance microglia for Alzheimer's, Phase 2b), AL101 (increases progranulin for Alzheimer's/Parkinson's, Phase 2), and preclinical ABC candidates ADP027-ABC (GPNMB) and ADP050-ABC (GCase).

Who are Alector's competitors?

Alector's competitors and similar companies include Canbex Therapeutics, AZ Therapies, Grin Therapeutics, Impulse Monitoring, and Arkis Biosciences.

Where is Alector headquartered?

Alector is headquartered in United States.

How many employees does Alector have?

Alector has 1,000 employees 🔒.

When was Alector founded?

Alector was founded in 2010 🔒.

What sector and industry vertical is Alector in?

Alector is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Alector

Who are the top strategic acquirers in Alector's sector and industry

Top strategic M&A buyers and acquirers in Alector's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Alector?

Top strategic M&A buyers groups and sectors for Alector include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Alector's sector and industry vertical

Which are the top PE firms investing in Alector's sector and industry vertical?

Top PE firms investing in Alector's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Alector's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Alector's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Alector's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Alector include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Alector's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Alector?

The key public trading comparables and valuation benchmarks for Alector include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Alector for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Alector with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Alector's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Alector with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Alector's' sector and industry vertical?

Access recent funding rounds and capital raises in Alector's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Alector